Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cerus Corporation
A drastic risk-off pullback in the public market can close an IPO window while private biotechs aspiring for either a public debut or an acquisition by big pharma may be stymied by their stale valuations.
Deal Snapshot: Following its January AI discovery alliance with Exscientia, Sanofi will employ Atomwise’s platform technology against five undisclosed drug targets.
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
- Infection Control-Sterilization